Investments	3 Months Ended
Jun. 30, 2013
Investments [Abstract]
Investments	Note 3 – Investments As part of the purchase of the assets of Opsolution GmbH the Company acquired an equity interest in Opsolution NanoPhotonics. Opsolution NanoPhotonics is not consolidated as the Company is not the primary beneficiary providing the majority of financial support to Opsolution NanoPhotonics. On February 28, 2013 the Company and Opsolution GmbH entered into a joint venture agreement to continue research and development of certain intellectual property. Upon execution of the joint venture agreement the Company is to provide funding of $100,000 toward the development by Opsolution of new prototypes. An additional $50,000 is to be paid over 8 month provided Opsolution GmbH meets certain investor and performance criteria. The Company is recognizing this research and development expense as the services are performed and the expenses are incurred. On June 14, 2013, the registrant’s wholly owned subsidiary, Biozoom Technologies, Inc. exercised its option, pursuant to its February 28, 2013 joint venture agreement with Opsolution GmbH, a German company, to acquire 19.9% of Opsolution GmbH for $9,950. This investment is accounted for under the cost method.

Investments

3 Months Ended

Jun. 30, 2013

Note 3 – Investments

As part of the purchase of the assets of Opsolution GmbH the Company acquired an equity interest in Opsolution NanoPhotonics. Opsolution NanoPhotonics is not consolidated as the Company is not the primary beneficiary providing the majority of financial support to Opsolution NanoPhotonics.

On February 28, 2013 the Company and Opsolution GmbH entered into a joint venture agreement to continue research and development of certain intellectual property. Upon execution of the joint venture agreement the Company is to provide funding of $100,000 toward the development by Opsolution of new prototypes. An additional $50,000 is to be paid over 8 month provided Opsolution GmbH meets certain investor and performance criteria. The Company is recognizing this research and development expense as the services are performed and the expenses are incurred.

On June 14, 2013, the registrant’s wholly owned subsidiary, Biozoom Technologies, Inc. exercised its option, pursuant to its February 28, 2013 joint venture agreement with Opsolution GmbH, a German company, to acquire 19.9% of Opsolution GmbH for $9,950. This investment is accounted for under the cost method.

Biozoom, Inc. 10-Q